Navigation Links
Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform

EAST FALMOUTH, Mass. and SUNNYVALE, Calif., July 8 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC) and MDS Analytical Technologies are pleased to announce the launch of ACC's Chromogenic LAL Endotoxin assay kits utilizing MDS Analytical Technologies' SpectraMax(R) instrument platform and SoftMax(R) Pro GxP software.

ACC and MDS Analytical Technologies collaborated on an FDA 21 CFR part 11 solution for ACC's Chromogenic LAL Endotoxin assay kits. The partnership was based on ACC's validation of MDS Analytical Technologies' VersaMax(TM) monochromator-based absorbance microplate reader using the SoftMax(R) Pro GxP software compliant environment.

ACC offers several chromogenic assays: Pyrochrome(R) and Chromo-LAL for endotoxin detection and Glucatell(R) to detect (1,3)-beta-D-glucan in industrial applications. All methods are optimized for use in microplate detection systems such as the VersaMax(TM) reader.

SoftMax(R) Pro 5 GxP software from MDS Analytical Technologies is the industry standard microplate analysis software, offering extensive data capture and analysis capabilities in a FDA 21 CFR Part 11 compliant environment for MDS Analytical Technologies' SpectraMax(R) line of microplate readers. It includes features that make it particularly well suited to endotoxin and glucan assays.

"We are proud to partner with one of the world's largest manufacturers of assay kits to detect endotoxin in drugs and biological products," said Andy Boorn, President of MDS Analytical Technologies. "Our pharmaceutical and biotechnology customers performing tests on the SpectraMax instrument platform can now increase their capital asset utilization by running LAL assays on SpectraMax readers. In addition, they can leverage the FDA 21 CFR Part 11 compliant system setup with SoftMax Pro GxP software reducing additional compliance costs required with third-party vendor solutions."

ACC President & CEO A.J. Meuse, Ph.D. added, "Partnering with MDS Analytical Technologies, one of the premier bioanalytical instrument companies in the world, further strengthens our ability to meet the variety of instrument and software requirements our customers have for endotoxin and (1,3)-beta-D-glucan analysis. We are pleased to offer our customers the VersaMax(TM) plate reader which provides additional functionality for product release testing in an FDA 21 CFR Part 11 compliant environment."

Customized assay methods for Chromo-LAL, Glucatell(R), Glucatell(R) Diazo, Pyrochrome(R), Pyrochrome(R) Diazo assay kits are available for SoftMax(R) Pro software version 5.2 GxP and greater.

About Associates of Cape Cod, Inc.

Associates of Cape Cod, Inc., based in East Falmouth, MA, is a leader in the field of bacterial endotoxin and beta-glucan detection and a major supplier to the pharmaceutical, medical device and clinical diagnostic industries. A wholly owned subsidiary of Seikagaku BioBusiness Corporation, the Company pioneered the humane use of the horseshoe crab blood extract, Limulus Amebocyte Lysate (LAL), used in the testing of pharmaceuticals, medical devices and biologics, for the presence of potentially toxic endotoxins and glucans. Our products are marketed throughout the world under the trade names Pyrotell(R), Glucatell(R), Pyrochrome(R) and Chromo-LAL. The Company offers contract testing for endotoxins and glucans, and has a research biochemical's division, Northstar BioProducts(TM), specializing in carbohydrate chemistry. The Company also produces a clinical diagnostic test, Fungitell(R), for use by physicians to aid in the diagnosis of invasive fungal infections, and runs the CLIA approved Beacon Diagnostics(R) Laboratory for patient sample analysis. For more information about Associates of Cape Cod, Inc. and our products, please visit our websites at: or or call us at 1-888-395-2221.

About MDS Analytical Technologies

MDS Analytical Technologies is a newly established unit of MDS Inc. and is comprised of two main lines of business. The Sciex product portfolio offers proven market leadership in mass spectrometry. The Molecular Devices product portfolio is the gold standard in high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Find out more at or

VERSAMAX is a trademark of MDS Analytical Technologies (US) Inc., and SPECTRAMAX and SOFTMAX are registered trademarks of MDS Analytical Technologies (US) Inc.

Contact Info:

For further information contact:


Cheri Salazar

Director, Global Marketing Communications

Molecular Devices, now part of MDS Analytical Technologies

(408) 548-6316

SOURCE Associates of Cape Cod, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company
2. Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line
3. J.D. Power and Associates Reports: A Vast Majority of Southern California Indian Gaming Casino Customers Express Desire for a Smoke-Free Environment
4. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
5. Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services
6. Blue Cross and Blue Shield of Florida Awarded Prestigious J.D. Power and Associates Award for Second Year
7. Booth Radiology Associates Chooses IDC To Complete Its Transition To Digital Imaging
8. Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals
9. J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers
10. Berkery Noyes Represents Princeton Media Associates in Its Sale to HMP Communications/Alta
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BioCurex, Inc.
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: